NEUROTECH PHARMACEUTICALS

Neurotech is developing an innovative delivery platform that delivers a biological agent over an extended period of time in order to slow the progression of retinal-based diseases. We aim to address an unmet need for effective, long-term treatments in retinal diseases... Neurotech was founded in 2000 with a mission to deliver biological therapeutics, through a sustained release cell-based delivery device, to the back of the eye allowing for longer delivery of therapeutic protein drugs, thus eliminating the need for frequent injections or topical drops. The Company's most advanced clinical program is to develop a treatment for macular telangiectasia type 2 (MacTel). The origins of this program were initiated in 2010, when Dr. Martin Friedlander and Dr. Alan Bird introduced us to the Lowy Medical Research Institute (LMRI) and the Lowy Family Group (LFG). LMRI's mission is to understand the causes of MacTel and translate these discoveries into novel treatments. LMRI evolved from the..

Also known as: Neurotech, Neurotech Pharmaceuticals, Inc.

Primary location: Cumberland United States